NCT05747274 (SRDK0921_APS) is a clinical trial of SRDK0921 in Kidney Transplant Rejection, sponsored by BioMAdvanced Diagnostics.

Who is sponsoring NCT05747274?

NCT05747274 is sponsored by BioMAdvanced Diagnostics.

What drugs are being tested in NCT05747274?

Interventions in NCT05747274: SRDK0921.

What condition does NCT05747274 study?

NCT05747274 studies Kidney Transplant Rejection.

Is NCT05747274 still recruiting?

NCT05747274 is currently completed. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT05747274: SRDK0921_APS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SRDK0921_ Analytical Performance Study

Completed Last updated 9 November 2023

What this trial tests

trial testing SRDK0921 in Kidney Transplant Rejection in 439 participants. Completed in 29 September 2023.

Timeline

21 September 2023

Primary endpoint
29 September 2023

29 September 2023

Quick facts

Lead sponsor	BioMAdvanced Diagnostics
Status	Completed
Study type	OBSERVATIONAL
Enrollment	439
Start date	21 September 2023
Primary completion	29 September 2023
Estimated completion	29 September 2023
Sites	1 location across France

Drugs / interventions tested

SRDK0921

Conditions studied

Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →

Sponsor

BioMAdvanced Diagnostics

Who can join

18 and older, any sex, with Kidney Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analytical Performance Study of the SRDK0921 IVD medical device (Kit and Software)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Kidney Transplant Rejection

Currently open trials in the same condition.

NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
NCT06564649 — PROACT Pilot Trial · active not recruiting
NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05747274 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioMAdvanced Diagnostics
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05747274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing